GlobeNewswire Inc | Jan 19, 2021 12:09PM EST

January 19, 2021

LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennifer Buell, President and COO of Agenus, and Dr. Steven ODay, CMO of Agenus, will participate in B. Riley Securities Oncology Investor Conference on January 20-21, 2021.

Agenus Fireside ChatDr. Jennifer BuellThursday, January 21, 202110:30am 11:00amThe live webcast can be accessed via this link: https://www.webcaster4.com/Webcast/Page/2433/39550

Dr. Jennifer Buell and Dr. Steven ODay will also participate in a panel discussion on novel immunotherapies. Please contact your B. Riley representative for details.

Replays for each event will be available on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations.

About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered inLexington, MA.For more information, please visitwww.agenusbio.comand our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.

Contact:Agenus Inc.Caroline Bafundo 212-994-8209Caroline.Bafundo@agenusbio.com